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Abstract: Förster resonance energy transfer (FRET) from luminescent terbium complexes 
(LTC) as donors to semiconductor quantum dots (QDs) as acceptors allows extraordinary 
large FRET efficiencies due to the long Förster distances afforded. Moreover, time-gated 
detection permits an efficient suppression of autofluorescent background leading to   
sub-picomolar detection limits even within multiplexed detection formats. These 
characteristics make FRET-systems with LTC and QDs excellent candidates for clinical 
diagnostics. So far, such proofs of principle for highly sensitive multiplexed biosensing 
have only been performed under optimized buffer conditions and interactions between real-life 
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clinical media such as human serum or plasma and LTC-QD-FRET-systems have not yet 
been taken into account. Here we present an extensive spectroscopic analysis of absorption, 
excitation and emission spectra along with the luminescence decay times of both the single 
components as well as the assembled FRET-systems in TRIS-buffer, TRIS-buffer with 2% 
bovine serum albumin, and fresh human plasma. Moreover, we evaluated homogeneous 
LTC-QD FRET assays in QD conjugates assembled with either the well-known, specific 
biotin-streptavidin biological interaction or, alternatively, the metal-affinity coordination of 
histidine to zinc. In the case of conjugates assembled with biotin-streptavidin no significant 
interference with the optical and binding properties occurs whereas the histidine-zinc system 
appears to be affected by human plasma. 
Keywords: FRET; quantum dots; terbium; luminescence lifetime; blood; plasma; clinical 
diagnostics; biotin; streptavidin; histidin; immunoassay 
 
1. Introduction 
Over the last decades, applications based on Förster Resonance Energy Transfer (FRET) have 
become very valuable tools for innumerable applications in the fields of medicine and biology [1-3]. 
Due to the r
−6 distance dependence of FRET it is possible to gain access not only to small structural 
changes in biological processes such as protein folding but also to kinetic data of reactions (e.g., 
enzymatic activity) and binding events. FRET is used in both heterogeneous and homogeneous 
immunoassays. In most assay types, the FRET pairs consist of combinations of organic dyes and 
fluorescent proteins (FPs) [4-7]. Using the well-characterized organic dye family as FRET probes has 
the advantage of a small size, which alleviates some bioconjugation issues and guarantees a small 
impact on the biomolecule. They also exhibit long-term storage stability in a wide range of media and 
facile use [8]. FPs likewise are easy to attach to biomolecules and have little influence on biological 
systems [9]. Moreover, they can be expressed within the biological system of interest (e.g., for live cell 
imaging). Nevertheless, these advantages are accompanied by some drawbacks that must be kept in 
mind when performing FRET experiments, such as a relatively small Stokes-Shift, broad emission 
spectra and photobleaching. The luminescence lifetime of dyes and FPs is usually in the nanosecond 
time-range, so that signal and background emission can only be distinguished via spectral information, 
not via temporal characteristics. However, especially in biological media an accurate spectral 
discrimination is complex due to high background from autofluorescence [10,11]. In addition the 
Förster distances (donor-acceptor distance, where the FRET efficiency is 50%) rarely exceed 6 nm [12]. 
All these hindrances complicate clinical diagnostics, where reproducibility and accuracy of multiple 
parameter measurements are extremely important. 
The FRET pair combination of luminescent terbium complexes (LTCs) as donors and semiconductor 
quantum dots (QDs) as acceptors overcomes the limitations mentioned above. High photostability, 
brightness and luminescence quantum yields, large Förster distances and an excellent temporal as well 
as spectral separation make this FRET-pair a powerful tool for multiplexed FRET measurements in a 
wide range of applications in research and diagnostics [13,14]. The long luminescence lifetime of the Sensors 2011, 11                  
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LTCs (in the milliseconds range) allows nearly background-free detection of the FRET-sensitized QD 
emission by time gated detection of fluorescence emission [15]. QDs were used as acceptors because 
of their suitability for multiplexed detection. The symmetric emission bands with a small FWHM (full 
width at half maximum) in combination with the tunable emission wavelengths largely facilitate the 
simultaneous determination of different analytes (so called multiplexing) compared to dyes or 
fluorescent proteins [16]. Although LTC-QD FRET pairs have proven to be very useful when 
performing biosensing in various buffer solutions, the very important aspect of measuring in real-life 
in vitro diagnostic media such as human plasma or serum has not yet been considered. However, the 
functionality of the FRET-pair must be preserved in these media in order to achieve the integration 
into many clinical diagnostics assays—a critical next step for utilizing these nanocrystalline materials. 
Human blood is a complex cocktail of many different substances, which can be classified   
mainly into two components: cells (40–45% of volume) and plasma (55–60% of volume) [17]. As 
disease-specific biomarkers are contained in the plasma, this part of the blood is most interesting for 
clinical diagnostics from point-of-care to high-throughput-screening. In addition autofluorescence, 
scattering and absorption are strongly reduced compared to measurements in whole blood. Nevertheless 
these effects can still greatly bias measurements [18] and must therefore be carefully observed. 
In this study we compare conjugation of LTCs to biocompatible QDs in buffer and plasma to 
evaluate the influence of plasma on photophysical properties and the sensing performance of several 
different LTC-QD-systems. For these purpose we chose two different conjugation systems, namely 
biotin (Biot) binding to streptavidin (sAv) and histidine (His) to zinc (Zn) metal affinity. LTC-conjugated 
sAv was binding to biotinylated QDs, whereas peptides functionalized with LTCs on one end and 
displaying a hexahistidine tag on the other end were assembled directly to the zinc-rich surface of 
DHLA-capped QDs. 
2. Experimental Section and Methods 
The LTC “Lumi4Tb” labeled to streptavidin (ca. 4.4 Lumi4Tb per sAv) was provided by 
Lumiphore Inc. (Richmond, CA, USA). For peptide labeling, N-hydroxysuccinimide-activated Lumi4-Tb 
(NHS-Lumi4-Tb) was provided by Lumiphore. The peptide utilized here consisted of the sequence 
H2N-G•SGAAAGLS•(His)6-amide and can be essentially subdivided into three modular components 
as indicated. The N-terminal amine extending from the G residue provides a unique site-specific 
handle for labeling with the NHS-Lumi4-Tb. The SGAAAGLS portion should form a short alpha-helix 
around the alanines which are then disrupted at each side by the glycines; this motif serves as a short 
intervening linker. Lastly, the C-terminal (His)6 provides for high-affinity assembly to the QDs while 
the amide blocks the terminal carboxyl. Overall, this peptide is meant to allow the Tb label to have 
close proximity to the QD for efficient FRET while not allowing direct contact with the QD surface. 
The peptide was labeled using the manufacturer’s suggested protocol and then purified, desalted, 
lyophilized and stored at −20 °C in a dessicator until used as previously described in detail [19]. 
Biotinylated QDots
TM with emission maxima at 529 (Biot-QD529), 653 (Biot-QD653) and 712 nm 
(Biot-QD712), respectively, were purchased from Invitrogen Inc. (Carlsbad, CA, USA) with an 
average of six Bio/QD. These QDs are assumed to be surface functionalized with a proprietary 
amphiphilic polymer [20]. 530 nm emitting and 580 nm emitting CdSe/ZnS core/shell along with Sensors 2011, 11                  
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615  nm emitting CdSe/CdS/CdZnS-alloy/ZnS multilayer or “onionskin” QDs were synthesized as 
described with some modifications [21]. These were then surface-functionalized and made water 
compatible with dihydrolipoic acid (DHLA) ligands as described. It is important to note, that the latter 
DHLA ligand imparts colloidal stability to the QD via its deprotonated terminal carboxyl, which has 
previously only allowed these materials to be used in basic media. 
The solvents used were 10 mM TRIS-buffer (pH 7.4) without any further additives, 10 mM   
TRIS-buffer (pH 7.4) with 2% bovine serum albumin (BSA), and human plasma collected from fresh 
blood (pH ~7.4). The latter were collected in accordance with all institutional regulations. The plasma 
was extracted from fresh blood before each measurement. For this purpose the blood was centrifuged 
for 30 minutes at 2,500 g directly after extraction and then the supernatant was used for measurements. 
Because of the strong plasma absorption (especially in the UV), it was diluted with water four times 
for absorption measurements. For all other measurements undiluted plasma was used. All experiments 
were performed at room temperature. 
Absorption spectra were recorded in 1 cm quartz cells with a UV-VIS-spectrometer (Lambda35, 
PerkinElmer, USA). Luminescence (emission and excitation) spectra and lifetimes were recorded in 
3 mm quartz cells with a fluorescence lifetime spectrometer (FLS920, Edinburgh Instruments, UK). 
For the lifetime measurements the samples were excited with a Xe flashlamp (50 Hz repetition rate at 
340 nm) for LTCs and with a diode-laser (405.6 nm center wavelength, 2 MHz repetition rate, 5 mW 
maximum average power) for the QDs. FRET-measurements were performed on an immunoanalysis 
platereader (IOM Nanoscan LF500, Berthold Detection Systems, Germany) with two photomultiplier 
tube (PMT) detection channels using changeable bandpass filters (Semrock, USA). All samples were 
excited with a pulsed 337.1 nm nitrogen laser system (SpectraPhysics, USA) with 128 shots at 30 Hz 
repetition rate and a pulse energy of ca. 30 µJ (at the sample) for Biot-sAv conjugates and 100 µJ (at 
the sample) for His-Zn conjugates. For all samples the LTC and the QD emission were recorded 
simultaneously in the two PMT channels (LTC channel and QD channel). Decay time curves were 
recorded from 0 to 10 ms after the excitation pulse in 1,000 bins of 10 µs. 
For all spectroscopic measurements the sample volume was 150 µL. All samples were mixed and 
incubated within the used media (QD-DHLA to LTC-pep assembly happened inside these media 
without pre-assembly). FRET-measurements were performed in 20 µL sample volume. Concentrations 
for absorption measurements were 1 µM for LTC-sAv, 10 µM for LTC-Pep, 50 nM for Biot-QDs and 
100 nM for QD-DHLA. Luminescence measurements were performed with concentrations of 1 µM 
LTC-sAv or LTC-Pep and 100 nM for all QDs, respectively. Detection of FRET in the Biot-sAv 
conjugate assays was performed with QD concentrations of 0.08, 0.15, 0.2, 0.25, 0.3, 0.38, 0.5, 0.75, 1, 
1.5 and 3 nM, respectively. The LTC-sAv concentration was kept constant at 3 nM. Detection of 
FRET in the His-Zn conjugate assays was performed with five times higher concentrations, i.e., QD 
concentrations from 0.4 to 15 nM and a constant LTC-Pep concentration of 15 nM. 
Luminescence decay times of LTCs, QDs and the FRET systems were calculated from the   
decay curves by multi-exponential fitting procedures (I  =  ∑(Axexp(−t/τx)); LTCs: two variable 
exponentials; QDs: three variable exponentials; FRET-system acceptors: three variable exponentials; 
FRET-system donors: three variable exponentials and one fixed exponential corresponding to the 
decay time of the unquenched donor). Mathematical fits were performed with FAST
TM software 
(Edinburgh Instruments). Sensors 2011, 11                  
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3. Results and Discussion 
For the evaluation of the influence of plasma on photophysical and binding properties, we first 
performed basic photophysical measurements with the donors and acceptors separately. Afterwards we 
conducted time-resolved and time-gated measurements of the different LTC-QD FRET pairs within 
Biot-sAv and His-Zn conjugate assays to show the influence of plasma on QD-based FRET for clinical 
assays. In order to state more precisely which of the components of plasma interact with the FRET 
partners, we performed comparative measurements in TRIS-buffer and TRIS-buffer containing BSA 
(at a mass fraction of two percent, which is comparable to the fraction of human serum albumin in 
blood plasma) and in human plasma. 
3.1. Photophysical Characterization of FRET-Donors and -Acceptors 
Human plasma is a medium, which shows extremely high absorbance in the UV (inset of Figure 1) 
due to the high concentration of proteins. Beyond ca. 310 nm the absorbance is much weaker, showing 
some typical peaks of hemoglobin absorption (Figure 1). Nevertheless, compared to fluorophores, 
which are usually highly diluted in clinical assays, the absorption of undiluted plasma is still large 
between 310 and 600 nm. This results in a simple attenuation of incoming excitation as well as 
outgoing emission light (at wavelengths shorter than 600 nm) that needs to pass through the plasma 
medium. Although this does not influence the photophysical or binding properties of the fluorophores, 
it needs to be taken into account for optical measurements. 
Figure 1. Absorbance spectrum (1 cm path length) of human plasma. The inset shows the 
absorbance below 308 nm, which was measured at 200-fold dilution and the absorbance 
values were multiplied by a factor of 200. 
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Due to the strong UV absorption, all of the following absorption spectra were measured beyond  
310 nm. For both the LTCs and the QDs the absorption spectra within the different media (TRIS 
buffer, TRIS buffer + BSA and plasma) are unchanged and small differences in intensity arise due to 
the strong background of plasma or BSA absorption, which needed to be subtracted to show the pure 
absorption of LTCs and QDs. Using very highly concentrated solutions of LTCs or QDs would Sensors 2011, 11                  
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overcome this problem. However, the high costs of both these materials usually limit such types of 
measurements. Even with some intensity deviations due to the correction for plasma and BSA 
absorption, the most important aspect of unchanged shapes of the absorption spectra are still obvious 
(Figure 2). 
Figure 2. Representative absorbance spectra (a) LTC-Pep (c = 10 µM, corrected by 
absorbance of media, plasma diluted to ¼) (b) Biot-QD705 (c = 50 nM, corrected by 
absorbance of media, plasma diluted to ¼). 
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In order to obtain a deeper look into the possible influences of BSA and plasma on the 
photophysical properties of LTCs and QDs, we performed luminescence measurements of the different 
components. The negligible emission intensity of plasma allowed the use of undiluted plasma for all 
emission-based experiments. In order to avoid significant absorption of excitation and emission light 
by plasma we chose 3 mm cells. The emission intensity of LTC-Pep is almost equally quenched by 
BSA and plasma [ca. 30%–cf. Figure 3(a)] whereas the emission intensity of LTC-sAv is only weakly 
influenced (with a decrease of ca. 10% - data not shown). This effect can be explained by the fact that, 
in case of the LTC-sAv, the LTC is already attached to the sAv protein and thus protected from further 
influence of plasma proteins. The much smaller peptide complex of LTC-Pep is more influenced by 
the plasma proteins. 
The QD emission spectra reveal an inconsistent picture of plasma and BSA influence. The strong 
absorption of undiluted plasma can still be seen very nicely within the different excitation spectra of 
the QDs [Figure 3(b)], where the absorption maximum of hemoglobin around 430 nm becomes visible 
as a minimum in the Biot-QD712 spectrum in plasma. For wavelengths beyond 500 nm the influence 
of plasma absorption on the excitation spectra is negligible. In the case of the Biot-QD712 luminescence 
quenching due to BSA is evident within the excitation and emission spectra [Figure 3(b,c)], whereas 
plasma only slightly decreases the emission intensity. The influence of BSA and plasma on the 
emission of the different Biot-QDs is not identical. For Biot-QD653 the influence of BSA and plasma 
on the emission intensities is almost negligible whereas the luminescence intensities of the   
Biot-QD529 decreases significantly from buffer to buffer+BSA to plasma (data not shown). We 
assume that static as well as dynamic quenching effects play different roles on these materials which 
are characterized by differently shapes (elongation of the QDs with increasing sizes [22]) and 
composition (QD529 and QD653: CdSe/ZnS; QD712: CdSeTe/ZnS). This was also confirmed by the Sensors 2011, 11                  
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fluorescence lifetime measurements (vide infra). The same inconsistent behavior can be found for the 
DHLA-capped QDs, where luminescence intensity quenching of plasma is very strong and BSA almost 
negligible for the smaller CdSe/ZnS QD-DHLA530 whereas the intensities are significantly quenched 
for both BSA and plasma for the larger CdSe/ZnS QD-DHLA580 (data not shown). The largest 
onionshell structured CdSe/CdS/CdZnS-alloy/ZnS QD-DHLA615 shows decreased emission intensity 
from buffer to buffer+BSA to plasma [Figure 3(d)]. 
Figure 3. Emission and excitation spectra in buffer and plasma (a) LTC-Pep emission 
spectrum (c = 1 µM) (b) Biot-QD712 excitation spectra (λem = 705 nm, c = 50 nM)   
(c) Biot-QD712 emission spectra (λex = 340 nm, c = 50 nM) (d) QD-DHLA615 emission 
spectra (λex = 340 nm, c = 100 nM). 
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Distinguishing the different quenching processes can be done by comparing the decrease in 
luminescence intensity to the decrease in luminescence lifetime. If the intensity ratio I0/I (unquenched 
to quenched intensity) equals the lifetime ratio τ0/τ, the quenching is purely dynamic. If I0/I > 1 and 
τ0/τ = 1, the quenching is purely static. If I0/I > τ0/τ > 1 the quenching is a combination of static and 
dynamic. Figure 4 shows typical luminescence decay curves of LTCs and QDs, respectively. The LTC 
decay curves show an almost mono-exponential in the millisecond lifetime range, whereas the QD 
decay curves are typically multi-exponential in the 1 to 100 nanoseconds regime. LTC curves were fit 
with a double-exponential function, whereas QD curves were fit with a triple-exponential. All lifetime 
data are gathered in Table 1. Sensors 2011, 11                  
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Table 1. LTCs: Luminescence lifetimes (τx) and intensity fractions (IF) of the single 
components and intensity averaged lifetime (<τ>). QDs: Luminescence lifetimes (τx), 
intensity averaged lifetime (<τ>) and Förster distances (R0) with the LTC-conjugates. 
  Media  τ1 (µs)  IF (%)  τ2 (µs)  IF (%)  <τ> (µs) 
LTC-Pep 
Buffer  1,373  6  2,620  94  2,545 
Buffer + BSA  1,179  16  1,983  84  1,852 
plasma  1,118  9  1,863  91  1,794 
LTC-Strep 
Buffer  941 9  2,606  91  2,455 
Buffer + BSA  933  10 2,390 90 2,249 
plasma  899  10 2,370 90 2,227 
  Media  τ1 (ns)  τ2 (ns)  τ3 (ns)  <τ> (ns)  R0 (nm) 
Biot-QD529 
Buffer  9  51  137  69 
5.4  Buffer + BSA  9  36  61  61 
plasma  9  30  58  53 
Biot-QD653 
Buffer  17 66  205  85 
10.7  Buffer + BSA  17 66  203  85 
plasma  22 63  303  75 
Biot-QD712 
Buffer  13  77  205  93 
11.1  Buffer + BSA  10  70  192  65 
plasma  18  98  266  161 
QD-DHLA530 
Buffer  5 20  100  33 
7  Buffer + BSA  6 23  112  43 
plasma  5 22  117  47 
QD-DHLA580 
Buffer  7  22  100  25 
7.8  Buffer + BSA  6  21  98  24 
plasma  7  20  96  10 
QD-DHLA615 
Buffer  9 26  106  36 
7.9  Buffer + BSA  11 27  121  19 
plasma  11 24  140  31 
Looking at the luminescence lifetime data of the LTC samples the trend is quite consistent with the 
intensity results. LTC-sAv shows a small decrease in lifetime by ca. 10% for both BSA and plasma 
and we thus assume a dynamic quenching process (I0/I = τ0/τ ≈ 10/9) due to interactions between  
LTC-sAv and the protein containing media. For LTC-Pep, the lifetime and intensity data indicate the 
same but stronger dynamic quenching process with I0/I = τ0/τ ≈ 10/7. As mentioned above this can be 
explained by the smaller size of the LTC-Pep, which is much more influenced by BSA and the plasma 
proteins than the LTC-sAv. It has been previously reported that BSA and human serum albumin 
(HSA) can form ternary complexes with LTCs, serving as stabilizers and additional antennas and thus 
increasing the luminescence intensity of such complexes [23,24]. Regarding our luminescence intensity 
and lifetime results, which point towards a dynamic quenching process, such behavior could not be 
found for the LTC complexes. However, in contrast to the enhancement experiments, where nM 
concentrations of BSA and HSA were used, our biological media contained µM concentrations of 
these components and at the same time nM concentrations of the FRET components. Sensors 2011, 11                  
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Figure 4. Luminescence decays of LTC donors and QD acceptors in buffer and plasma  
(a) LTC-Pep (λex = 340 nm, λem= 545 nm, accumulation time = 5 min, c = 1 µM)  
(b) QD-DHLA615 (λex = 405.6 nm, λem= 615 nm, accumulation time = 5 min, normalized 
to area under curve, c = 100nM). 
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For the different QDs the behavior of the lifetimes in the different media is again inconsistent. Only 
Bio-QD653 (paralleling the intensity data) is not significantly influenced by BSA and plasma within 
the experimental errors. For Biot-QD529 an increasing lifetime quenching can be observed from BSA 
to plasma, although the quenching is weaker, which points to a combination of static and dynamic 
quenching (I0/I > τ0/τ > 1). A similar trend can be found for QD-DHLA580 and QD-DHLA615 in 
plasma and QD-DHLA712 in BSA-buffer. QD-DHLA580 and QD-DHLA615 show the same lifetimes 
for TRIS-buffer with or without BSA, but the intensity is significantly quenched (stronger for   
QD-DHLA580). This behavior can possibly be explained by a static quenching (I0/I > 1 and τ0/τ = 1) 
due to attachment of BSA to the QD surface via electrostatic interaction. QD-DHLA530 shows an 
unexpected behavior of quenched intensity and increasing lifetime from buffer to BSA to plasma, 
which could result from a static attachment of proteins (denser protein layer for plasma compared  
to BSA) to the QD surface (intensity quenching) accompanied by a structural influence on the 
photophysical properties of the QD, leading to an increase of the longer time components within the 
multi-exponential QD decay. The same effect but with a much stronger increase of the long lifetime 
component accompanied by a strong decrease of the shortest one and a decent decrease of intensity can 
be found for the Biot-QD712 in plasma. Moreover, this is in complete contradiction to the behavior in 
BSA-containing buffer, where the average lifetime decreases similarly to the intensity. 
Serum albumin is known to bind a lot of different substances through hydrophobic bonds and 
electrostatic interactions [25,26], and non-specific binding of plasma proteins, mainly of HSA, to QD 
surfaces has been shown before [27-29]. Nanoparticles in solution are stabilized by electrostatic and/or 
steric effects. The former increase with increasing surface charge, the latter increase with increasing 
particle size and functional surface groups, which can interact with the media [30]. In our spectroscopic 
study we could not find a clear trend of specific interactions of plasma components with the QDs and 
there was no clear difference between the interaction with the polymer coated large Biot-QDs and the 
DHLA surface-capped rather small QD-DHLAs. We conclude that our measurements fit to the somehow 
general picture of semiconductor quantum dots within aqueous or biological media: not every QD is 
alike [31]. Sensors 2011, 11                  
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3.2. FRET-Assays 
Immunoassays are very important for clinical diagnostics. Homogenous assays allow fast, 
inexpensive and highly sensitive detection, because they do not require any time-consuming washing and 
separation steps [32]. FRET can be used to detect biomolecular recognition processes and is one of the 
most sensitive detection methods for homogeneous immunoassays [33]. Besides high sensitivity and 
specificity, two challenges are of paramount importance for homogeneous FRET assays: the suppression 
of autofluorescence from the biological media and the possibility of measuring several parameters 
simultaneously (multiplexing). Both of these aspects can be efficiently fulfilled by LTCs, which offer 
long luminescence lifetimes and thus the possibility of time-gating and sufficient suppression of 
background, and QDs, which can be used in different colors as FRET acceptors with LTCs and thus 
offer the possibility of multiplexing [16]. 
3.2.1. Specific Binding Assays with Biotin and Streptavidin  
Biot-sAv binding is a widely used model system for specific biological binding because of the high 
binding affinity (dissociation constant of the biotin-streptavidin binding is about 10
−13 M [34]). Adding 
Biot-QDs to LTC-sAv leads to a quenching of the LTC luminescence and the appearance of new, 
shorter, time components, distinguishable by the change of the donor decay curves from an almost 
mono-exponential behavior (with max. 10% of a shorter time component) for LTC alone to a   
multi-exponential shape. These shorter lifetime components are the FRET-quenched decay times. The 
related FRET-sensitized decay times for the QD-acceptors are visible in the acceptor luminescence 
curves, which increase in intensity due to FRET-sensitization. Figure 5 shows representative   
LTC-to-QD FRET luminescence decay curves in the different media at different concentrations. All 
decay curves show the same trend of FRET-sensitized QD emission appearing in the acceptor channel 
(Figure 5 left) and FRET-quenched LTC emission in the donor channel (Figure 5 right). 
Figure 5. Decay curves of LTC-sAv and Biot-QD653  in plasma, LTC concentration 
c = 3 nM,  increasing  QD  concentration  (1:0.025 = 0.075 nM, 1:0.067 = 0.2 nM and 
1:1 = 3 nM)  (left) QD acceptor channel (background corrected) (right) LTC donor 
channel.  
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An important aspect for the sensitivity and reproducibility of time-resolved homogeneous FRET 
assays is the calculation of the ratio of time-gated emission intensities of the donor and the acceptor [16]. 
A so-called ratiometric measurement calibration curve displays the intensity ratio as a function of the 
analyte concentration, or in our case the QD acceptor concentration at a fixed LTC donor concentration 
(Figure 6). The calibration curve displays a steep rise of the ratio for BSA-buffer and plasma 
measurements after addition of small amounts of Biot-QD. The curve reaches a plateau at a sAv to 
Biot concentration ratio of ca. 6:1 in BSA-buffer, in good agreement with the average amount of six 
Biot molecules on the QD surface. In plasma this saturation effect is less abrupt and occurs later 
(around unity). For pure TRIS buffer measurements, no saturation is observable within the measured 
concentration range. The difference in ratios is caused by a different increase of sensitized acceptor 
luminescence with increasing QD concentrations. In plasma and BSA-buffer the polystyrene walls of 
the microwell plates are saturated with proteins and non-specific binding of Biot-QD or LTC-sAv  
is strongly suppressed [35,36] and all the FRET partners are free in solution. In protein-free buffer  
this non-specific binding is not suppressed and the FRET signal is much lower for small   
LTC-sAv-Biot-QD concentrations. We assign the difference in the calibration curves of BSA and 
plasma to the many different components within the plasma, which can non-specifically bind to the 
QD surface. This stronger non-specific binding compared to BSA causes a less efficient binding of 
LTC-sAv to Biot-QD and thus saturation at higher concentrations.  
Figure 6. Ratio of sensitized acceptor emission and donor emission IA/ID for LTC-sAv 
(3 nM) and Biot-QD653 (signal intensity integrated over time window 0.01–10 ms). 
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The limits of detection (LODs) of all LTC-sAv-Biot-QD systems were calculated by using the 
concentration value (within the linearly rising part of the calibration curves) of the blank ratio (no 
Biot-QDs) plus three times the standard deviation of 30 blank measurements (cf. Table 2). All   
Biot-QD systems show sub-nanomolar LODs in protein containing media. The pure buffer values are 
significantly higher due to the non-specific binding problems discussed above. The LODs are in 
agreement with the weaker luminescence quenching effects for Biot-QD653 and 712 in plasma 
compared to Biot-QD529 (vide supra), for which also the LOD is significantly higher for plasma 
measurements. The systems of LTC-sAv and Biot-QD653 and Biot-QD705 are very well suited for 
clinical assays because their detection limits are in the low picomolar range. Sensors 2011, 11                  
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Table 2. Limits of detection (LODs ± 20% deviation) for the different LTC-QD FRET 
pairs for the specific (Biot-sAv) and metal affinity coordination (His-Zn) assays in the 
different biological media. 
  LOD in nM 
LTC-sAv  buffer  buffer + BSA  plasma 
Biot-QD529 0.27  0.0064 0.30 
Biot-QD653 0.51  0.0047 0.018 
Biot-QD712 0.13  0.0017 0.0026 
LTC-Pep     
QD-DHLA530 5.2  0.63  - 
QD-DHLA580 2.6  2.9  - 
QD-DHLA615 0.11  0.28  - 
 
3.2.2. Metal Affinity Coordination Assays with Zinc and Polyhistidine 
 
In contrast to the specific sAv-Biot interactions, we utilize metal affinity coordination between His-Zn 
as an alternate QD bioconjugation method. A growing number of groups have demonstrated that this 
interaction can be exploited for assembling proteins, peptides and even DNA to QDs functionalized with 
a number of different types of surfaces or ligands [20,38]. Polyhistidine binds with high affinity to 
certain metal ions, including especially nickel, copper, cobalt, manganese, iron and especially zinc. 
The binding is a result of the sharing of electron density between histidine’s imidazole nitrogen with 
the electron-deficient orbitals of transition metals. The binding between polyhistidine and the zinc on 
QD surfaces is known to be extremely stable with a dissociation constant of ~1 × 10
−9 M [39]. Using 
the Zn
2+-rich surface of QDs and hexahistidine-tagged peptide assembly we have successfully applied 
this mechanism to create a number of different FRET and charge transfer based biosensors that were 
capable of monitoring DNA hybridization, enzymatic activity and pH changes [2,38,40]. 
In TRIS buffer and BSA-containing buffer the addition of small amounts of QD-DHLA to a solution 
of LTC-Pep leads to an immediate FRET-sensitization of the QD-acceptor emission demonstrating an 
efficient binding of the histidine-tagged LTC-peptides to the QD surface. Although experiments have 
shown that up to 50 ± 10 peptides can bind to the surface of the QD [41], we found a saturation at ca. 
10 peptides/QD within our ratiometric calibration curves, which might be caused by the low 
concentrations applied in our assays, being close to the dissociation constant (ca. 1 nM) of the 
hexahistidine-peptide-QD binding system [39]. Thus, our saturation value is rather a natural binding 
equilibrium than a maximum occupation of binding sites. The higher dissociation constant compared 
to Biot-sAv could lead to a lower fraction of quenched donors, because most of the donors and 
acceptors are unbound in solution. Nevertheless, the still relatively high ratio of donors per acceptor 
after addition of small amounts of QDs leads to a significant FRET-signal increase (Figure 7). 
Analogous to the Biot-sAv assays, FRET leads to sensitized acceptor emission and quenched donor 
emission and the time-gated intensity ratios are recorded.  
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Figure 7. Ratio of sensitized acceptor emission and donor emission IA/ID for LTC-Pep  
(15 nM) and QD615-DHLA (signal intensity integrated over time window 0.01–10 ms). 
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Due to the much lower dissociation constant for Biot-sAv binding, the LODs of the   
QD-DHLA-LTC-Pep systems are significantly larger compared to the Biot-sAv systems. As the   
QD-DHLA-LTC-Pep system does not include any proteins, non-specific binding to the well walls is 
not a problem and thus the addition of BSA does not have a strong influence on the LODs, which even 
slightly increase with addition of BSA. Surprisingly, and in contrary to the photophysical properties, 
which showed almost no difference between buffer with or without BSA, QD-DHLA530 revealed a 
very bad assay performance in pure TRIS-buffer but relatively low LODs within BSA-containing 
buffer; reinforcing the hypothesis that individual QD responses can change drastically due to subtle 
surface perturbations.  
For all QD-DHLA-LTC-Pep systems in plasma no trace of FRET could be observed even at 
equivalent ratios of donors and acceptors neither for acceptor nor for donor emission. The small 
increase of ratio over QD concentration (Figure 7) is caused by the strong fluorescence from directly 
excited QDs. This signal can still be measured after hundreds of microseconds. As the influence of 
plasma on the photophysical properties of the single components is not at all sufficiently strong to 
explain such a behavior, we assign this lack of FRET to a very inefficient binding of the His6-tag of the 
donor to the ZnS-shell caused by a plasma component. Human serum albumin can be excluded 
because measurements in BSA-containing buffer show very obvious FRET signals. Therefore other 
compounds of the plasma must prevent the binding. Most likely transferrin and the histidine-rich 
glycoprotein, which can be found in physiological concentrations of 60 µM and 2.5 µM, respectively, 
are responsible for this. These proteins are known to bind to Zn
2+ with a dissociation constant of  
~10
−6 M [42,43] and can compete successfully with the polyhistidine-tag of the peptide-labeled LTC, 
which is present in the assay at ca. three orders of magnitude lower concentrations. The prevention of 
the His-Zn binding in plasma needs to be taken into account, when this binding system is applied for 
clinical diagnostics. 
4. Conclusions 
FRET from LTCs as donors to QDs as acceptors in blood plasma has, for the first time, been 
described in this study. Two different conjugation systems were used to simulate two prominent types Sensors 2011, 11                  
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of QD assembly. A photophysical characterization of all donors and acceptors was performed in TRIS 
buffer, BSA-containing TRIS buffer, and fresh human plasma. The LTCs were mainly influenced by a 
dynamic quenching process due to interactions with BSA or the plasma proteins. The QDs gave a 
much more inconsistent picture of interactions with BSA or plasma with a combination of static and 
dynamic quenching mixed with some structural stabilization effects. However, all these different 
influences could not be clearly assigned to the different QD properties, thus leading us to the 
conclusion that even though there are similarities in size, shape or material composition, no QD is 
alike. Specific binding assays used conjugates assembled with biotinylated QDs and streptavidin-labeled 
LTCs, whereas conjugates based on His-Zn binding were realized with DHLA-capped QDs and 
peptide-labeled LTCs. Besides some unexpected effects for the smaller QDs, the principal finding is 
that for direct use in plasma and similar types of environments, QD assemblies should be initially 
based on biotin-avidin interactions or other alternative covalent chemistries [44]. 
The results for DHLA-capped QD assemblies in plasma were not entirely unexpected for a number 
of interrelated reasons. Given that experiments were performed at pH 7.4, where such QDs can become 
colloidally unstable in conjunction with using sample concentrations that are at the His-Zn dissociation 
point did not initially allow for anywhere near optimal conditions. Moreover, the DHLA can be 
charged which would also serve to attract oppositely charged species and contribute to fouling of the 
surface. Most critically, our experiments (focusing on a simple direct assay) utilized a format where 
the nanocomplexes were assembled stepwise in the plasma itself. Namely, the media was aliquoted, 
then the QDs were added followed by the LTC-pep in the last step and left to incubate for 1 hour. It is 
most probable that this configuration allowed a number of proteins and other biological molecules and 
ions to interact with and potentially block the QD surface. Moreover, plasma is known to have high 
concentrations of ions (Mg, Fe, etc.) that can and will also interact with and block the polyhistidine’s 
coordination and binding capacity.  
These results, however, do not broadly discount assemblies based on His-Zn from such media, they 
rather suggest that either this assembly order or the DHLA ligand itself may be unsuitable for such 
media. More pertinently, we know of no assay formats that have successfully utilized DHLA QDs 
directly in plasma or blood. In contrast, initial QD assembly using His-Zn interactions have already 
been shown to be viable in the highly reducing intracellular environment and similar QD conjugates 
have been shown to remain assembled within the highly acidic cellular endolysosomal system of live 
cells for several days; this used QDs displaying either amphiphilic polymers or poly(ethylene glycol) 
(PEG) surfaces, respectively [45,46]. PEG ligands are broadly used in this field to functionalize QDs 
and make them water soluble. They provide two inherent benefits: (1) solubility is mediated by the 
uncharged ethylene oxide repeats allowing broad pH stability and (2) they are inherently antifouling. A 
further benefit in the current context is that their large size sterically prevents proteins, but not 
peptides, and other large molecules from accessing the QDs Zn surface [21]. Cumulatively, this should 
prevent charged species and proteins from fouling the QD surface and competing to remove assembled 
His-appended peptides. Another possibility in this direction is the use of QDs functionalized with 
compact zwitterionic ligands; these are also known for their broad pH stability and antifouling 
characteristics [21]. Future experiments will focus on improving CdSe/ZnS-polyhistidine viability in 
plasma by testing of QDs displaying these improved surfaces, more judicious control over relative QD 
concentrations in assays, iterative characterization of pre-assembly versus direct assembly in plasma Sensors 2011, 11                  
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along with extending the number of histidine repeat residues which should improve binding to the QD 
surface to an even higher affinity [39].  
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